Anti IgLON5 antibody syndrome: treatment
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Anti IgLON5 antibody syndrome: treatment. Methylprednisolone, Plasma exchange (PE), Rituximab. Fully referenced neurology checklist.
Treatment
- Methylprednisolone
- Plasma exchange (PE)
- Rituximab
- Intravenous immunoglobulins (IVIg)
- Adjunctive cyclophosphamide: case report
Predictors of treatment response
Locked: subscribe to see this section.
References
- Sabater L, Gaig C, Gelpi E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol 2014; 13:575-586.
- Schröder JB, Melzer N, Ruck T, et al. Isolated dysphagia as initial sign of anti-IgLON5 syndrome. Neurol Neuroimmunol Neuroinflamm 2016; 4:e302.
- Gaig C, Graus F, Compta Y, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology 2017; 88:1736-1743.
- Honorat JA, Komorowski L, Josephs KA, et al. IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm 2017; 4:e385.
- Grüter T, Gaig C, Crijnen YS, et al. Early treatment with intravenous immunoglobulins and outcomes of patients with anti-IgLON5 disease. JAMA Neurol 2025; 82:1040-1047.
- And 4 more. Subscribe to see the full list
